Roni Shouval

4.7k total citations · 2 hit papers
109 papers, 1.8k citations indexed

About

Roni Shouval is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Roni Shouval has authored 109 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 44 papers in Hematology and 14 papers in Molecular Biology. Recurrent topics in Roni Shouval's work include CAR-T cell therapy research (45 papers), Hematopoietic Stem Cell Transplantation (34 papers) and Acute Myeloid Leukemia Research (23 papers). Roni Shouval is often cited by papers focused on CAR-T cell therapy research (45 papers), Hematopoietic Stem Cell Transplantation (34 papers) and Acute Myeloid Leukemia Research (23 papers). Roni Shouval collaborates with scholars based in United States, Israel and France. Roni Shouval's co-authors include Arnon Nagler, Joshua Fein, Avichai Shimoni, Ivetta Danylesko, Mohamad Mohty, Ron Unger, Miguel‐Angel Perales, Ronit Yerushalmi, Noga Shem‐Tov and Myriam Labopin and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roni Shouval

102 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

2024 99 citations Roni Shouval, Miguel‐Angel Perales et al. profile →
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients

2024 44 citations Roni Shouval, Miguel‐Angel Perales et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roni Shouval United States	26	695	678	310	235	207	109	1.8k
Joshua Fein United States	16	354 0.5×	480 0.7×	261 0.8×	140 0.6×	220 1.1×	46	1.2k
Alix E. Seif United States	31	1.4k 2.0×	804 1.2×	520 1.7×	836 3.6×	710 3.4×	122	3.1k
Attilio Guarini Italy	25	616 0.9×	533 0.8×	558 1.8×	219 0.9×	434 2.1×	112	2.1k
Mohamed E. Salama United States	31	611 0.9×	675 1.0×	1.2k 3.9×	127 0.5×	200 1.0×	135	3.1k
Frank Kroschinsky Germany	24	598 0.9×	875 1.3×	277 0.9×	232 1.0×	314 1.5×	85	2.3k
Semra Paydaş Türkiye	28	1.0k 1.5×	563 0.8×	627 2.0×	123 0.5×	319 1.5×	208	2.7k
Marion Rabant France	32	285 0.4×	219 0.3×	566 1.8×	411 1.7×	659 3.2×	147	3.6k
Mei‐Chin Wen Taiwan	18	287 0.4×	141 0.2×	204 0.7×	78 0.3×	167 0.8×	85	1.3k
Friedrich Stölzel Germany	22	409 0.6×	1.0k 1.5×	539 1.7×	241 1.0×	215 1.0×	92	1.9k
Branimir Jakšić Croatia	15	328 0.5×	344 0.5×	209 0.7×	161 0.7×	467 2.3×	136	1.7k

Countries citing papers authored by Roni Shouval

Since Specialization

Citations

This map shows the geographic impact of Roni Shouval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roni Shouval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roni Shouval more than expected).

Fields of papers citing papers by Roni Shouval

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roni Shouval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roni Shouval. The network helps show where Roni Shouval may publish in the future.

Co-authorship network of co-authors of Roni Shouval

This figure shows the co-authorship network connecting the top 25 collaborators of Roni Shouval. A scholar is included among the top collaborators of Roni Shouval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roni Shouval. Roni Shouval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shouval, Roni, Shalev Fried, Ivetta Danylesko, et al.. (2025). Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells. Blood Advances. 9(7). 1720–1725. 1 indexed citations

Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2024). Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Current Research in Translational Medicine. 72(4). 103471–103471. 5 indexed citations

Dusza, Stephen W., et al.. (2024). Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System. Transplantation and Cellular Therapy. 30(10). 1035.e1–1035.e7. 2 indexed citations

Youngster, Ilan, Ivetta Danylesko, Israel Henig, et al.. (2024). Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study. Bone Marrow Transplantation. 59(3). 409–416. 7 indexed citations

Pophali, Priyanka A., Joshua Fein, Kwang Woo Ahn, et al.. (2024). CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma. Blood Advances. 8(20). 5290–5296. 6 indexed citations

Magen, Hila, Shalev Fried, Orit Itzhaki, et al.. (2023). POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematological Oncology. 41(S2). 82–83. 1 indexed citations

Devlin, Sean M., Beatriz Wills, Amethyst Saldia, et al.. (2023). Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy. Blood. 142(Supplement 1). 3510–3510. 1 indexed citations

Ryan, Christine E., Rebecca L. Zon, Robert Redd, et al.. (2023). Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement. British Journal of Haematology. 203(5). 774–780. 8 indexed citations

Fried, Shalev, Ivetta Danylesko, Orit Itzhaki, et al.. (2023). High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia. Blood. 142(Supplement 1). 6875–6875.

10.

Fried, Shalev, Orit Itzhaki, Ronit Yerushalmi, et al.. (2023). Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leukemia & lymphoma. 64(12). 1956–1963. 3 indexed citations

11.

Zhou, Yiwang, Jesse Smith, Cai Li, et al.. (2023). Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning. Blood Advances. 8(3). 686–698. 2 indexed citations

12.

Shouval, Roni & Joshua Fein. (2023). The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation. Hematology. 2023(1). 715–722. 2 indexed citations

13.

Fried, Shalev, Roni Shouval, Nira Varda‐Bloom, et al.. (2022). Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia & lymphoma. 63(14). 3385–3393. 5 indexed citations

14.

Goldman, Adam, Emanuel Raschi, Joab Chapman, et al.. (2022). Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. Blood. 141(6). 673–677. 8 indexed citations

15.

Hadanny, Amir, Roni Shouval, Jianhua Wu, et al.. (2021). Machine learning-based prediction of 1-year mortality for acute coronary syndrome✰. Journal of Cardiology. 79(3). 342–351. 11 indexed citations

16.

Goldman, Adam, Emanuel Raschi, Tali Cukierman‐Yaffe, et al.. (2021). Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology. 29(9). 1334–1342. 25 indexed citations

17.

Shouval, Roni, Amir A. Kuperman, Ivetta Danylesko, et al.. (2020). Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Blood Advances. 4(13). 2912–2917. 42 indexed citations

18.

Shouval, Roni, Myriam Labopin, David Bomze, et al.. (2020). Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation. 55(12). 2244–2253. 6 indexed citations

19.

Danylesko, Ivetta, Roni Shouval, Noga Shem‐Tov, et al.. (2020). Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation. 56(5). 1134–1143. 23 indexed citations

20.

Shouval, Roni, Annalisa Ruggeri, Myriam Labopin, et al.. (2017). An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clinical Cancer Research. 23(21). 6478–6486. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact